iShares Nasdaq Biotechnology ETF (IBB) Holdings Cut by Rothschild Capital Partners LLC

Rothschild Capital Partners LLC decreased its stake in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 1.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,190 shares of the financial services provider’s stock after selling 321 shares during the quarter. iShares Nasdaq Biotechnology ETF comprises 1.1% of Rothschild Capital Partners LLC’s holdings, making the stock its 25th biggest position. Rothschild Capital Partners LLC’s holdings in iShares Nasdaq Biotechnology ETF were worth $2,034,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Princeton Global Asset Management LLC acquired a new stake in shares of iShares Nasdaq Biotechnology ETF in the fourth quarter worth $460,000. Castle Rock Wealth Management LLC increased its stake in shares of iShares Nasdaq Biotechnology ETF by 4.8% in the fourth quarter. Castle Rock Wealth Management LLC now owns 2,274 shares of the financial services provider’s stock worth $250,000 after acquiring an additional 105 shares during the period. McGuire Investment Group LLC increased its stake in shares of iShares Nasdaq Biotechnology ETF by 0.7% in the first quarter. McGuire Investment Group LLC now owns 35,839 shares of the financial services provider’s stock worth $4,007,000 after acquiring an additional 250 shares during the period. Albion Financial Group UT increased its stake in shares of iShares Nasdaq Biotechnology ETF by 1.3% in the fourth quarter. Albion Financial Group UT now owns 101,575 shares of the financial services provider’s stock worth $9,795,000 after acquiring an additional 1,273 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of iShares Nasdaq Biotechnology ETF in the fourth quarter worth $1,191,000. Institutional investors and hedge funds own 67.92% of the company’s stock.

Shares of NASDAQ:IBB traded down $0.57 during midday trading on Friday, reaching $103.87. The company’s stock had a trading volume of 43,772 shares, compared to its average volume of 2,913,010. iShares Nasdaq Biotechnology ETF has a twelve month low of $89.01 and a twelve month high of $122.97.

COPYRIGHT VIOLATION NOTICE: “iShares Nasdaq Biotechnology ETF (IBB) Holdings Cut by Rothschild Capital Partners LLC” was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://transcriptdaily.com/2019/05/17/ishares-nasdaq-biotechnology-etf-ibb-holdings-cut-by-rothschild-capital-partners-llc.html.

iShares Nasdaq Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Story: Can systematic risk be avoided?

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.